In conclusion, these data from animal studies suggests that STARD4 knockdown suppresses tumorigenesis and enhances the anti-tumor effect of lenvatinib in vivo by inhibiting EGFR/PI3K/AKT signaling pathway. This evidence concerns the gene AKT1 and neoplasm.